Epitope-based approaches to a universal influenza vaccine

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 15-20

  Gottlieb, Tanya ^a   Ben Yedidia, Tamar ^a  

^a BiondVax Pharmacuticals Ltd   (Israel)

Author keywords

Influenza; Multimeric 001; Pandemic; Peptide; Seasonal; Vaccines

Indexed keywords

EPITOPE; INFLUENZA VACCINE;

ARTICLE; AVIAN INFLUENZA VIRUS; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; PANDEMIC INFLUENZA; RNA SEQUENCE; SEASONAL INFLUENZA; VACCINE PRODUCTION; VIRUS STRAIN; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; INFLUENZA, HUMAN; MORTALITY; PANDEMIC;

CLINICAL TRIALS AS TOPIC; EPITOPES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

EID: 84908376119     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.07.005     Document Type: Article

References (67)

1. Orthomyxoviruses: influenza 1998, Arnold. N. Cox, Y. Kawaoka (Eds.).
2. Webster R., Laver W., Air G., Schild G. Molecular mechanism of variation in influenza viruses. Nature 1982, 296(5853):115-121.
3. Receptor specificity, host-range, and pathogenicity of influenza viruses 2006, Caister Academic Press. M. Matrosovich, H. Klenk, Y. Kawaoka (Eds.).
4. Kirchenbaum G.A., Ross T.M. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 2014, 12(28C):71-76.
5. http://www.cdc.gov/flu/about/qa/vaccineeffect.htm.
6. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169.
7. http://www.cdc.gov/flu/about/qa/flushot.htm.
8. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005, 366(9492):1165-1174.
9. http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/may2110vaxprod.html.
10. http://www.cidrap.umn.edu/news-perspective/2012/11/fda-clears-first-cell-based-flu-vaccine.
11. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82:488-496.
12. http://www.cdc.gov/vaccinesafety/Concerns/h1n1_narcolepsy_pandemrix.html.
13. Flahault A., Vergu E., Boëlle P.Y. Potential for a global dynamic of influenza A (H1N1). BMC Infect Dis 2009, 9:129. 12.
14. http://www.phe.gov/Preparedness/mcm/H1N1-retrospective/Documents/H1N1-retrospective.pdf.
15. http://www.examiner.com/x-29691-Boulder-Healthy-Living-Examiner~y2010m1d4-H1N1-Swine-Flu-Vaccine-Update-European-countries-selling-excess-H1N1-swine-flu-vaccine.
16. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.html.
17. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet 2008, 8:650-658.
18. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
19. Keogh-Brown M, McDonald S, Edmunds WJ, Beutels P, Smith RD. The macroeconmic costs of a global influenza pandemic. In press, https://www.gtap.agecon.purdue.edu/resources/download/3828.pdf.
20. Lee B.Y., Bartsch S.M., Willig A.M. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30:7443-7446.
21. Yetter R., Lehrer S., Ramphal R., Small Pj Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 1980, 29(2):654-662.
22. Kreijtz J.H., Bodewes R., van den Brand J.M., de Mutsert G., Baas C., van Amerongen G., et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009, 27(36):4983-4989.
23. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., et al. Mechanisms of heterosubtypic immunity to lethal influenza a virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. JImmunol 1997, 158(3):1222-1230.
24. Wunderlich K., Mayer D., Ranadheera C., Holler A.S., Mänz B., Martin A., et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS One 2009, 4(10):e7517.
25. Skountzou I., Koutsonanos D.G., Kim J.H., Powers R., Satyabhama L., Masseoud F., et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. JImmunol 2010, 185(3):1642-1649.
26. Boon A.C., deBeauchamp J., Krauss S., Rubrum A., Webb A.D., Webster R.G., et al. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. JVirol 2010, 84(15):7662-7667.
27. Tu W., Mao H., Zheng J., Liu Y., Chiu S.S., Qin G., et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. JVirol 2010, 84(13):6527-6535.
28. Liu W., Li H., Chen Y. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003, 35:141-146.
29. Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., et al. Auniversal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009, 27(15):2099-2107.
30. Furuya Y., Chan J., Regner M., Lobigs M., Koskinen A., Kok T., et al. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza a viruses. JVirol 2010, 84(9):4212-4221.
31. Ben-Yedidia T., Beignon A., Partidos C., Muller S., Arnon R. Aretro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol Immunol 2002, 39(5-6):323-331.
32. Scherle P., Gerhard W. Functional analysis of influenza-specific helper T cell clones invivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. JExp Med 1986, 164(4):1114-1128.
33. Russell S., Liew F. Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of virion. Eur J Immunol 1980, 10(10):791-796.
34. Hans D., Young P., Fairlie D. Current status of short synthetic peptides as vaccines. Med Chem 2006, 2(6):627-646.
35. Rötzschke O., Falk K., Stevanović S., Jung G., Walden P., Rammensee H. Exact prediction of a natural T cell epitope. Eur J Immunol 1991, 21(11):2891-2894.
36. Ben-Yedidia T., Arnon R. Design of peptide and polypeptide vaccines. Curr Opin Biotechnol 1997, 8(4):442-448.
37. Snyder J., Belyakov I., Dzutsev A., Lemmonier F., Berzofsky J. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. JVirol 2004, 78:7052-7060.
38. Hsu S., Chargelegue D., Obeid O., Steward M. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. JGen Virol 1999, 80(Pt 6):1401-1405.
39. Azizi A., Diaz-Mitoma F. Viral peptide immunogens: current challenges and opportunities. JPept Sci 2007, 13(12):776-786.
40. Kashala O., Amador R., Valero M.V., Moreno A., Barbosa A., Nickel B., et al. Safety, tolerability and immunogenicity of new formulations of the plasmodium falciparum malaria peptide vaccine spf66 combined with the immunological adjuvant QS-21. Vaccine 2002, 20(17-18):2263-2277.
41. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. JInfect Dis 2000, 182(5):1486-1496.
42. Engler O.B., Dai W.J., Sette A., Hunziker I.P., Reichen J., Pichler W.J., et al. Peptide vaccines against Hepatitis B virus: from animal model to human studies. Mol Immunol 2001, 38(6):457-465.
43. Gahery H., Daniel N., Charmeteau B., Ourth L., Jackson A., Andrieu M., et al. New cd4+ and cd8+ T cell responses induced in chronically hiv type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res Hum Retroviruses 2006, 22(7):684-694.
44. Pinto L.A., Berzofsky J.A., Fowke K.R., Little R.F., Merced-Galindez F., Humphrey R., et al. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 1999, 13(15):2003-2012.
45. Martinez O., Tsibane T., Basler C. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol 2009, 28(1):69-92.
46. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses. Nat Struct Mol Biol 2009, 16(3):265-273.
47. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6(2):e1000796.
48. Khurana S., Loving C.L., Manischewitz J., King L.R., Gauger P.C., Henningson J., et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 2013, 5(200):200ra114. 28.
49. Stouffer A., Acharya R., Salom D., Levine A.S., Costanzo L.D., Soto C.S., et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451(7178):596-599.
50. Zharikova D., Mozdzanowska K., Feng J., Zhang M., Gerhard W. Influenza type A virus escape mutants emerge invivo in the presence of antibodies to the ectodomain of matrix protein 2. JVirol 2005, 79(11):6644-6654.
51. Wang Y., Zhou L., Shi H., Xu H., Yao H., Xi X.G., et al. Monoclonal antibody recognizing SLLTEVET epitope of M2e protein potentialy inhibited the replication of influenza viruses in mdck cells. Biochem Biophys Res Commun 2009, 385(1):118-122.
52. Testa J.S., Shetty V., Hafner J., Nickens Z., Kamal S., Sinnathamby G., et al. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One 2012, 7(11):e48484.
53. Ichihashi T., Yoshida R., Sugimoto C., Takada A., Kajino K. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One 2011, 6(9):e24626.
54. http://www.its-innovation.com/index.php.
55. Stoloff G., Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 2007, 37(9):2441-2449.
56. Pleguezuelos O., Robinson S., Stoloff G.A., Caparrós-Wanderley W. Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. Vaccine 2012, 30(31):4655-4660. 29.
57. http://www.clinicaltrials.gov/ct2/show/NCT01226758?term=flu+v%26rank=2.
58. Ben-Yedidia T., Marcus H., Reisner Y., Arnon R. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int Immunol 1999, 11:1043-1051.
59. Gottlieb T., Hassin S., Ben-Yedidia T. Preparedness ahead of pandemic outbreaks. BioProcess Int 2013, 11(S9):20-25.
60. Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., et al. Auniversal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009, 27(15):2099-2107. 26.
61. http://www.BiondVax.com.
62. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280.
63. Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, etal. Priming by a novel universal influenza vaccine (multimeric-001) - a gateway for improving immune response in the elderly population. Vaccine, in press.
64. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM330392.pptx.
65. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. JAutoimmun 2012, 39:117-120.
66. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. JAutoimmun 2013, 45:97-103.
67. Gershwin M.E., Shoenfeld Y. Abul Abbas: an epitome of scholarship. JAutoimmun 2013, 45:1-6.